HCPCS Level II S0172: Chlorambucil, Oral, 2 mg

HCPCS Level II code S0172 identifies chlorambucil, oral, 2 mg, a cytotoxic alkylating agent used in oncology and hematology. As a drug-specific HCPCS Level II code, S0172 facilitates standardized billing and reimbursement for dispensing or administration of this oral chemotherapy agent across outpatient and pharmacy settings. Nationally, clear coding for antineoplastic agents supports care coordination, benefit determinations, and cost tracking for cancer treatments.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. These payers commonly establish coverage policies and prior authorization requirements for oral oncology agents, making correct HCPCS coding essential for claims processing and patient cost-sharing calculations.

Readers will gain a concise overview of what S0172 represents, the typical sites where services associated with the code occur, and how the code fits into billing workflows. The publication also covers payer coverage landscape, common modifiers associated with HCPCS drug billing, and the clinical context in which chlorambucil may be used. Data not provided in the input for payor-specific rates, taxonomies, ICD-10 pairings, and related procedure codes is noted as unavailable.

Billing Code Overview

HCPCS Level II code S0172 represents Chlorambucil, oral, 2 mg, an oral antineoplastic medication used in the treatment of certain cancers and hematologic malignancies. The code denotes the drug product and strength for billing purposes.

Service Type: Oral chemotherapy medication administration / pharmacy-dispensed drug

Typical Site of Service: Outpatient clinic, physician office, or pharmacy

Clinical Context

A typical patient is an adult with a hematologic malignancy such as chronic lymphocytic leukemia (CLL) or low-grade non-Hodgkin lymphoma who receives oral chemotherapy with chlorambucil for cytoreduction or maintenance therapy. The prescribing oncologist or hematologist documents indication, planned dose (commonly 2 mg tablets), treatment schedule, concurrent medications, and baseline labs (CBC, renal and liver function). The workflow includes an office visit for evaluation and informed consent, entry of the prescription into the electronic medical record and specialty pharmacy or outpatient infusion pharmacy, verification of drug coverage and prior authorization if required, medication counseling by a pharmacist or nurse (adverse effects, monitoring, dosing adjustments), and scheduled laboratory monitoring during therapy. Follow-up visits occur with toxicity assessment and dose modification as needed. Typical sites of service are outpatient oncology clinics, physician offices, and outpatient pharmacies dispensing oral chemotherapy.

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier — standard service	Use when no special circumstances apply and service is billed as usual.
`22`	Increased procedural services

Taxonomy Code	Specialty	Notes
`207RH0000X`	Hematology & Oncology	Oncology and hematology specialists prescribe and manage chlorambucil therapy.
`207RC0000X`	Medical Oncology	Medical oncologists manage systemic chemotherapy regimens and monitoring.
`2080P0004X`	Hematology	Hematologists provide diagnosis and long-term management for leukemias and lymphomas.
`3336S0206X`	Oncology Pharmacy Specialist	Specialty pharmacists provide counseling, dosing verification, and coordination with payors.
`363L00000X`	Nurse Practitioner	Advanced practice clinicians in oncology clinics who manage prescriptions and follow-up.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C91.10`	Chronic lymphocytic leukemia of B-cell type, not having achieved remission	Chlorambucil is an oral alkylating agent used historically for cytoreduction in CLL.
`C83.30`	Diffuse large B-cell lymphoma, unspecified, extranodal and solid organ sites	Alkylating agents may be part of regimens or salvage therapy in selected low-intensity settings.
`C85.90`	Non-Hodgkin lymphoma, unspecified, unspecified site	Chlorambucil can be used for indolent non-Hodgkin lymphoma subtypes.
`D61.9`	Aplastic anemia, unspecified	Not an indication for chlorambucil; included as a code to avoid — relevant for monitoring hematologic toxicity if present.
`Z92.21`	Personal history of antineoplastic chemotherapy	Used to document prior exposure to chemotherapy when managing ongoing oral therapy.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`99213`	Office or other outpatient visit for the evaluation and management of an established patient, typically 15 minutes	Used for routine oncology follow-up visits to assess tolerance, lab results, and medication management for oral chlorambucil.
`99214`	Office or other outpatient visit for the evaluation and management of an established patient, typically 25 minutes	Used for more complex follow-up visits requiring moderate to high medical decision making or extensive counseling regarding oral chemotherapy.
`99605`	Medication therapy management services for a new patient	Used by pharmacists for initial medication therapy management when initiating oral anticancer therapy.
`36415`	Collection of venous blood by venipuncture	Used for baseline and ongoing laboratory monitoring (CBC, chemistry panels) associated with chlorambucil therapy.
`85025`	Complete blood count (CBC) with automated differential	Common laboratory test performed before and during therapy to monitor for myelosuppression related to chlorambucil.

OpenPayer

Summary & Overview